DefiniGEN's platform technology enables the generation of predictive and phenotypically relevant iPSC-derived human disease models for a wide range of metabolic and liver diseases which can be produced at scale.
Combine our expertise at generating iPSC-derived hepatocyte disease models with our wide panel of bespoke bioassays. We work as partners with your team to design and implement in-house screening of small molecules and advanced genetic therapies, so you can advance your program at speed.
DefiniGEN has a large panel of iPSC lines allowing us to offer all our disease models and cell-based bioassays in donors ranging in gender, age and ethnicity. Researchers use our donor panels to further screen their lead candidates and potentially inform the stratification of a successful clinical trial.
Specialist CRO focused on delivering liver and metabolic disease models
Highly Predictive
Opti-HEPs successfully recapitulate key aspects of disease pathophysiology across a wide-range of conditions that affect different aspects of liver function
Scalable
DefiniGEN’s proprietary differentiation protocol permits large-scale generation of hepatocyte-like cells with field leading purity and functionality
Optimized Bioassay Development
Optimized bioassays that can accurately evaluate compound potency, efficacy and delivery
Scientific expertise
15
15 successful and recurring partnerships with leading cell and gene therapy companies
10
10 years of iPSC innovation
6
6 in-house validated disease models ready for screening
10
10 years of supporting R&D with our innovative, proprietary iPSC endodermal protocols
Advance your scientific discoveries with our tailored disease modeling products and services
